Key result
Endocrine disorders and estrogen exposure may modify the development and progression of pulmonary hypertension.
Why the study?
Co-existing medical conditions may contribute to the genesis and progression of pulmonary hypertension, but the role of concomitant endocrine disorders and their pathogenetic routes needed summarization.
Do endocrine disorders (thyroid disorders, obesity, diabetes mellitus, estrogen exposure) modify the development and progression of pulmonary hypertension?
Do endocrine disorders (thyroid disorders, obesity, diabetes mellitus, estrogen exposure) modify the development and progression of pulmonary hypertension?
Understanding the role of concomitant endocrine conditions in pulmonary hypertension can help clinicians better evaluate and manage this patient population.
Pulmonary hypertension (PH) is a progressive disorder characterized by a chronic in-crease in pulmonary arterial pressure, frequently resulting in right-sided heart failure and potentially death. Co-existing medical conditions are important factors in PH, since they not only result in the genesis of the disorder, but may also contribute to its progression. Various studies have assessed the impact of thyroid disorders and other endocrine conditions (namely estrogen exposure, obesity, and diabetes mellitus) on the progression of PH. The complex interactions that hormones may have with the cardiovascular system and pulmonary vascular bed can create several pathogenetic routes that could explain the effects of endocrine disorders on PH development and evolution. The aim of this review is to summarize current knowledge on the role of concomitant thyroid disorders, obesity, diabetes mellitus, and estrogen exposure as potential modifiers for PH, and especially for pulmonary arterial hypertension, and to discuss possible pathogenetic routes linking them with PH. This information could be valuable for practicing clinicians so as to better evaluate and/or treat concomitant endocrine conditions in the PH population.
No takes yet. Share an insight, caveat, or question.
Vrigκou et al. (2022) conducted a review in Pulmonary hypertension. Endocrine disorders (thyroid disorders, obesity, diabetes mellitus, and estrogen exposure) was evaluated. Thyroid disorders, obesity, diabetes mellitus, and estrogen exposure may act as important modifiers in the development and progression of pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: